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Acromegaly is usually not a difficult condition to diagnose once the possibility of this disease has been
raised. However, a few conditions present with some aspects of acromegaly or gigantism but without
growth hormone (GH) excess. Such cases are described as "pseudoacromegaly" or "acromegaloidism".
Here we describe a female patient investigated for GH excess at 10 years of age for tall stature since
infancy (height and weight. +3 standard deviations) and typical acromegalic features, including large
hands/feet, large jaw, tongue, hoarse deep voice, and headache. Results of radiography of the sella
turcica and GH response at an oral glucose tolerance test and insulin–arginine– thyrotrophin–
luteinizing hormone–releasing hormone test were normal. Ethinylestradiol and medroxyprogesterone
were given for 2 years; this successfully stopped further height increase. Although the patient’s growth
rate plateaued, coarsening of the facial features and acral enlargement also led to investigations for
suspicion of acromegaly at 23 and 36 years of age, both with negative results. On referral at the age of
49 years, she had weight gain, sweating, sleep apnea, headaches, joint pain, and enlarged tongue.
Endocrine assessment again showing normal GH axis was followed by genetic testing with amacrocephaly/
overgrowth syndrome panel. A de novo mutation in the NSD1 gene (c.6605G.C; p.Cys2202Ser) was
demonstrated. Mutations affecting the same cysteine residue have been identified in patients with Sotos
syndrome. In summary, Sotos syndrome and other overgrowth syndromes can mimic the clinical man-
ifestations of acromegaly or gigantism. Genetic assessment could be helpful in these cases.
Copyright © 2017 Endocrine Society
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Diagnosis of acromegaly is often delayed several years after onset of symptoms [1]. However,
once the disease is suspected, the diagnostic process is usually uncomplicated [2]. Patients
occasionally present with clinical aspects of acromegaly or gigantism but without growth
hormone (GH) excess: pseudoacromegaly or acromegaloidism. Here we present such a case
and the diagnostic work-up.
1. Case Report
In 2012, a 49-year-old womanwas referred to the endocrine clinic for suspicion of acromegaly.
This was her fourth referral and investigation for suspected GH excess since the age of
10 years.
Abbreviations: EU, European Union; GH, growth hormone; SD, standard deviation; UK, United Kingdom.
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There was no family history of abnormal growth: The patient’s mother’s height was 164 cm
(20.2 standard deviation [SD]), her father’s height was 175 cm (20.5 SD), and both her
brother and her sister were of normal height. She was born at 41 weeks’ gestation, her length
at birthwas 52 cm (+1 SD), and her birthweight was 4120 g (+1.5 SDs). At 9months of age, she
weighed 16 kg (. +3 SDs), and her shoe sizewas 28 in theEuropean (EU) sizing scheme. From
age 7 years, her height was above +3 SDs. She had her first teeth at 2 months, and at age 3
years permanent teeth began to replace her deciduous teeth (normal age range, 5 to 7 years);
at age 8 years, she had the teeth maturation of a 12-year-old. Her performance in school was
below average, with difficulties in concentration and learning. However, no formal cognitive
tests were performed. The parents did notice her early accelerated growth rate, but because
she was their first child they did not seek medical attention [Fig. 1(a)].
At 10 years of age, she was seen by an ophthalmologist because of apparent visual
problems. Ophthalmologic status, includingGoldmann perimetry, was normal, but as a result
of apparent acromegalic features she was referred to the pediatric clinic. She was large, at a
height of 160 cm (. +3 SDs) andweight of 60 kg (. +3 SDs), with skeletal age corresponding to
15 years and a full set of permanent teeth except wisdom teeth. However, pubertal devel-
opment corresponded to her chronologic age: Tanner stages I (breast) and II (pubic hair).
Typical acromegalic features were noted: large hands and feet [shoe size, 43 EU], large jaw
and tongue, and hoarse and deep voice. Endocrine evaluation (GH, oral glucose tolerance test,
insulin–arginine–thyrotrophin-releasing hormone–luteinizing hormone–releasing hormone
test, other pituitary hormones, and radiography of the sella turcica) was normal. She was
treated with ethinylestradiol and medroxyprogesterone; this treatment successfully reduced
and stopped further gain in height but increased her weight gain. Treatment was finally
discontinued because of heavy menstrual bleeding and development of a uterus myoma after
almost 2 years’ treatment. At this point (age 12 years), her height was 171 cm and her weight
was 78 kg.
During the next 40 years, she trained and worked as an assistant nurse. She had an
operation for carpal tunnel syndrome (age 32 years), hallux valgus (age 34 years), and os-
teoarthritis in her wrist (age 45 years). Because of endometriosis and large endometrial cysts,
Figure 1. Patient at ages 5 (a) and 49 (b) years.
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she had a left salpingo-oophorectomy and resection of a rather large cyst in the right ovary at
age 31 years. At age 39 years she noted vitiligo; she was also diagnosed with mild hyper-
thyroidism due to an autonomous thyroid nodule, which was treated with radioiodine fol-
lowed by stable 125 mg/d L-thyroxine replacement therapy. She is also receiving oral vitamin
B12 treatment.
At 23 years of age, she was referred to the endocrine clinic because of clinical suspicion of
acromegaly. Endocrine evaluation, including a GH curve, was normal, and no pituitary
adenoma was found on pituitary computed tomography.
At 36 years of age, she was referred from a fertility clinic, where acromegaly was again
suspected; endocrine evaluation was repeated and again was normal. Efforts to induce
pregnancy, including in vitro fertilization, were unsuccessful. The couple adopted a daughter
in 2003.
At 49 years of age, she was referred for the fourth time for suspicion of acromegaly with
fatigue, increasing swelling of hands and feet, and increasing size of the tongue. She also had
numbness; weight gain; pain in the knees, hands, fingers, and lumbar back; headaches; and
depression. She was increasingly troubled with sweating and snoring. At the time of this
referral, the magnitude of her health problems had led to sick leave. She was generally obese
(height, 175 cm; weight, 112 kg; body mass index, 36.6 kg/m2); her blood pressure was 125/
75 mm Hg; and she showed acromegalic features, with moderate enlargement of the tongue,
nose, and lips, large hands (index finger diameter, 28 mm), and feet (shoe size, 45 EU) [Fig.
1(b)]. Results of routine laboratory tests, including pituitary hormone levels, were un-
remarkable. Magnetic resonance imaging of the sella showed no pituitary adenoma, and
endocrine evaluation showed noGH excess, with an insulin-like growth factor-1 level of 205 to
213 mg/L (reference range, 54 to 307 mg/L), normal GH day curve (mean GH level, 0.167 mg/L;
minimum, 0.034 mg/L), and normal GH suppression in response to an oral glucose tolerance
test (GH minimum, 0.033 mg/L).
Because of her history of excessive growth in childhood, genetic testing with a panel for
macrocephaly/overgrowth syndrome genes was performed.
2. Genetic Studies
DNA was isolated from whole blood by using the QIAamp DNA Blood Maxi kit (Qiagen,
Hilden, Germany). Sequencing of the proband’s genomic DNA for the macrocephaly/
overgrowth syndromes panel (NSD1, CUL4B, EZH2, GLI3, MED12, NFIX, PHF6, PTCH,
PTEN, andUPF3B) was performed at GeneDx (Gaithersburg,MD) using aHiSeq instrument
(Illumina, San Diego, CA). Confirmation of the proband’s mutation and her parents’ geno-
typing were performed with Sanger sequencing (primers: ACCAGCAGGGAAATGGGAAT
and GGAGGCACATACTCACGGAT).
A heterozygous mutation was identified in the NSD1 gene (c.6605G.C; p.Cys2202Ser)
(Fig. 2). This variant has not been previously described, but mutations affecting the same
cysteine residue (C2202R and C2202Y) have also been reported in the HumanGeneMutation
Database in association with Sotos syndrome and gigantism [3]. This mutation is located in
the fifth plant homeodomain (PHD-V), a cysteine- and histidine-rich zinc finger–like motif,
where other missense mutations have also been described in patients with Sotos syndrome
[4]. The mutation has likely arisen de novo because it was not identified in the analysis of the
patient’s parents’ genome (Fig. 2).
3. Discussion
Sotos syndrome (Mendelian Influence in Man 117550) was first described by Sotos et al. in
1964, as a congenital overgrowth syndrome with clinical features, including excessive
overgrowth with advanced bone age, acromegalic features, macrocephaly, characteristic
facial appearance, and intellectual disability [5–8]. Additional features that may be present
include neonatal hypotonia, neonatal jaundice, seizures, scoliosis, strabismus, congenital
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heart defects, hypothyroidism, hypopigmentation, and cancer [5–8]. Because macrocephaly
is a feature of the syndrome, "cerebral gigantism" was an early term for this condition.
Interestingly, a note in the pediatric records of our patient stated that clinical features of
cerebral gigantism were absent (age 10 years).
In 2002, the syndrome was associated with haploinsufficiency of the nuclear receptor SET
domain protein 1 (NSD1) gene on chromosome 5, first in caseswithmicrodeletions of 5q35 and
later also with intragenic mutations of the NSD1 gene, which is the most common cause of
Sotos syndrome [7]. Sotos syndrome is an autosomal dominant disorder, and most cases are
due to de novo mutations [7, 8]. These data suggest that the underlying NSD1 mutational
mechanism may influence reproductive function, and delayed menarche, oligomenorrhea,
spontaneous abortions, and stillbirths have been reported in patients with Sotos syn-
drome [9].
NSD1 encodes a histone methyltransferase involved in chromatin regulation, which is
important for multiple aspects of normal embryonic development. NSD1 binds near various
promoter elements to regulate transcription via interactions with histone H3 methylation
and recruitment of RNA polymerase II and has been suggested to both negatively and
positively regulate transcription [7]. In addition to its causal role in Sotos syndrome, NSD1
is a proto-oncogene, and epigenetic alterations induced by NSD1 may also be implicated in
malignancies [7, 8].
Although pituitary gigantism and acromegaly were suspected and excluded repeatedly in
this patient, the correct diagnosis, Sotos syndrome, was delayed for several decades. Sotos
syndromewas first described in 1964, and the pediatric evaluation in our patient took place in
1974. In current pediatric practice, tall stature with advanced bone age and some level of
Figure 2. Sequencing electropherogram of NSD1 exon 23 from the patient (top) and her
parents (bottom). The double peak (in blue) confirms the presence of a de novo heterozygous
missense mutation at c.6605G.C (p.Cys2202Ser). No mutation was found in the patient’s
mother and father.
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learning difficulties would lead to suspicion of Sotos syndrome [10]. However, the wide
variability of the phenotype of Sotos syndrome associatedwithNSD1mutations canmake the
diagnosis very difficult [6–8]. Although most individuals with Sotos syndrome have mild
intellectual disability, normal intellectual ability has also been reported [7, 11]. In the current
case, no formal cognitive testing was performed, but intellectual and social functions were
considered to bewithin the normal range. Another discrepancywith current pediatric practice
is that sex steroids are no longer widely recommended to halt growth because of their short-
and long-term consequences [10], and the possibility that this treatment contributed to our
patient’s infertility cannot be excluded.
In addition to Sotos syndrome, the differential diagnosis for acromegaly/pituitary gi-
gantism, include several genetic overgrowth syndromes, such as Beckwith–Wiedemann
(IGF2),Weaver (EZH2),Malan (NFIX), andTatton–Brown–Rahman (DNMT3) syndromes, or
diseases that feature tall stature, such as Berardinelli–Seip lipodystrophy (AGPAT2) or
abnormalities of natriuretic peptide C pathway (NPR2, CNP) [8, 10, 12–14]. In adults with
acromegaloid features, pachydermoperiostosis should also be considered [15].
This case illustrates that genetic overgrowth syndromes should be considered as differ-
ential diagnoses in patients with acromegaloid features without excess GH secretion, a group
of conditions also called pseudoacromegaly. As genetic diagnostic testing is becoming more
accessible and affordable, it should be considered in these patients to allow correct diagnosis
and relevant monitoring and treatment of concomitant health problems related to the
syndrome, such as ophthalmologic and psychiatric disease and possibly increased risk for
malignancies. Our patient was grateful and relieved to finally receive a diagnosis because it
explained her symptoms and signs and allowed her to be treated symptomatically.
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